You are here: Industry Insights > atezolizumab

News List

Roche gets first checkpoint inhibitor OK in breast cancer pharmaphorum
March 12, 2019
Roche’s Tecentriq was the third PD-1/PD-L1 inhibitor to reach the market but is the first in class to be approved for any form of breast cancer
FDA Approves Atezolizumab with Chemotherapy and Bevacizumab for First-Line Treatment of Metastatic Non-Squamous NSCLC americanpharmaceuticalreview
December 10, 2018
On December 6, 2018, the Food and Drug Administration approved atezolizumab (TECENTRIQ, Genentech, Inc.), in combination with bevacizumab, paclitaxel, and carboplatin .....
Roche pulls extended use application for kidney cancer drug pharmaphorum
November 26, 2018
Roche has withdrawn an application to the European Medicines Agency (EMA) for an expanded use for its immunotherapy drug, Tecentriq....
Roche's Tecentriq+chemo combo shows first-line benefit in small cell lung cancer pharmafile
September 27, 2018
Roche has unveiled new Phase 3 data for its cancer immunotherapy Tecentriq (atezolizumab) in combination with carboplatin and etoposide chemotherapy as a first-line treatment...
NICE backs Roche’s Tecentriq for pre-treated bladder cancer pharmatimes
July 12, 2018
Roche’s Tecentriq will be routinely available on the NHS in England and Wales to patients with advanced, pre-treated bladder cancer, following a nod from cost-regulators.
Immunotherapy treatment fast-tracked under UK’s access to medicines scheme europeanpharmaceuticalreview
February 06, 2017
From today, UK patients with an incurable form of bladder cancer can access the new immunotherapy, atezolizumab.

Previous page 1 2 Next page